Pulmonary survival study in 91 patients with systemic sclerosis

Area of Science:

• Rheumatology
• Pulmonology
• Internal Medicine

Background:

• Pulmonary complications, including interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), are major causes of morbidity and mortality in systemic sclerosis (SSc).
• Understanding the natural course of pulmonary involvement in SSc is crucial for timely diagnosis and management.

Purpose of the Study:

• To investigate the natural course of pulmonary involvement in patients with systemic sclerosis (SSc).
• To analyze pulmonary survival based on the development of ILD and PAH in SSc patients.

Main Methods:

• A historical cohort study involving 91 SSc patients in Iran (1998-2007).
• Pulmonary interstitial involvement assessed by high-resolution CT scan (HRCT).
• Pulmonary hypertension evaluated by echocardiography; secondary outcomes included abnormal FVC or DLCO.

Main Results:

• ILD developed after a median of 107 months; pulmonary fibrosis occurred in 31.9% of patients.
• Alveolitis and fibrosis developed at median times of 129 and 259 months, respectively.
• Pulmonary alveolitis developed significantly later in the limited SSc subtype (P=0.03), though overall pulmonary survival differences between subtypes were not significant in Cox regression analysis.

Conclusions:

• Clinical manifestations of limited and diffuse SSc subtypes, initially divergent, converge in later stages regarding pulmonary involvement.
• Early detection of pulmonary involvement in SSc patients using echocardiography and pulmonary function tests is recommended to prevent significant vascular and fibrotic changes.